Zosano Pharma Corporation reported impairment charges for the first quarter ended March 31, 2022. For the quarter, the company reported impairment loss of $25.9 million for the three months ended March 31, 2022, consists of the write-down of $24.8 million of property and equipment and $1.1 million of right-of-use assets.
Zosano Pharma Corporation
Equities
ZSAN
US98979H3012
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |